Table 3.
Relative Risk* Ponesimod versus Teriflunomide |
|
---|---|
Primary endpoint | |
Annualised relapse rate per year | –30% |
Secondary endpoints | |
12-week confirmed disability accumulation | –17%** |
Cumulative no. of combined unique active lesions | –55% |
Change in FSIQ score | –3.6 point (between-arm difference) |
Exploratory endpoints | |
24-week confirmed disability accumulation | –16%** |
Cumulative no. of gadolinium-enhancing lesions | –58% |
Change in whole brain volume | 0.34% (between-arm difference) |
NEDA-3 | +70% |
NEDA-4 | +85% |
Notes: *Unless indicated otherwise; **Not statistically significant.
Abbreviations: FSIQ, Fatigue Symptom and Impact Questionnaire; NEDA, no evidence of disease activity.